Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 18;51(9):4126–4147. doi: 10.1093/nar/gkad268

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 11. — HSD17B13 silencing with low, single dose. (A) Dosing regimen for transgenic HSD17B13 mice, with dosing at day 0 (D0) and tissue evaluation at the indicated time in weeks (W) post-dose. HSD17B13 mRNA levels in liver of transgenic mice treated with the indicated siRNA at 1.5 or 3.0 mg/kg 12-weeks post-dose. Data are presented as scatter plots with lines denoting mean mRNA levels, n ≥ 4. Stats: One-way ANOVA with post-hoc test comparison to PBS ****P < 0.0001. (B) Concentration of antisense strands in livers 12-weeks post-dose for the indicated treatment. Data are presented as mean ± sd, n ≥ 4. (C) Relative Ago2 loading for antisense strands in mouse livers over time with normalization to miR-122. Data are presented as mean ± sd, n = 5. Stats: Unpaired, two-tailed t test * P < 0.05.